ClearRead CT vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

ClearRead CT

by RIVERAIN TECHNOLOGIES

EchoNext

by Pathway Labs

AI Verdict

ClearRead CT and EchoNext are adjacent competitors, both focusing on cardiovascular health but utilizing different diagnostic modalities. ClearRead CT enhances CT scan analysis for pulmonary nodules and coronary artery calcification, streamlining radiology workflows. EchoNext, on the other hand, analyzes standard ECGs to detect hidden structural heart disease, offering a non-invasive screening tool for earlier detection.

Choose ClearRead CT if…

Choose ClearRead CT if your radiology department needs to enhance the detection and analysis of pulmonary nodules and coronary artery calcification directly from CT scans. This tool is ideal for improving diagnostic accuracy, reducing reading times, and streamlining workflows through its advanced AI and patented vessel suppression technology, especially in cardiology and pulmonology specialties.

View ClearRead CT →

Choose EchoNext if…

Choose EchoNext if your practice or hospital aims to non-invasively screen for hidden structural heart disease, such as heart failure, valve disease, and pulmonary hypertension, using standard ECGs. This AI tool is particularly well-suited for broad access across various clinical settings, from major hospitals to community practices, offering an affordable and accessible diagnostic support solution.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	ClearRead CT	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	On-premise (stand-alone server, virtual machine) and Cloud	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ClearRead CT

ClearRead CT emphasizes seamless integration into existing PACS workflows, allowing radiologists to review AI-processed images alongside original scans without needing a separate application or extra clicks. This direct integration and concurrent reading capability significantly streamlines the user experience and reduces cognitive burden. EchoNext, while integrating with the OpenEvidence platform, still relies on an external platform for deployment, which might introduce an additional layer to the workflow for some users.

Clinical Value

ClearRead CT

ClearRead CT has demonstrated a 29% reduction in missed actionable nodules and a 36% reduction in total reading time for CT scans, with studies showing improved detection sensitivity for lung nodules. EchoNext has shown high accuracy in detecting structural heart disease from ECGs, outperforming cardiologists in some studies, and has been credited with leading to earlier diagnoses and even a heart transplant. However, ClearRead CT's impact on reducing missed nodules and reading time directly addresses critical challenges in radiology, offering a more quantifiable and immediate clinical workflow improvement.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts, making it easier for potential customers to understand the cost. ClearRead CT's pricing is listed as 'contact for pricing,' which offers less transparency upfront. While both offer significant clinical value, EchoNext's clear pricing structure provides better initial value assessment for potential buyers.

Enterprise Readiness

ClearRead CT

ClearRead CT offers both on-premise and cloud deployment options, supports vendor-neutral processing across all CT manufacturers, and seamlessly integrates with PACS, RIS, and EMRs. This broad compatibility and flexible deployment make it highly adaptable for diverse enterprise environments. EchoNext is available through the OpenEvidence platform, which has a wide reach, but its deployment options are less explicitly detailed beyond this platform.

Innovation

Tie

ClearRead CT features patented vessel suppression technology and automated nodule tracking and comparison, offering unique advancements in CT scan analysis. EchoNext is innovative as the world's first FDA-cleared AI tool to detect multiple types of hidden structural heart disease from standard ECGs, a significant breakthrough in cardiac screening. Both tools present significant and distinct innovations within their respective domains, making it difficult to declare one a clear winner in this dimension.

Support & Docs

Tie

Both companies indicate a focus on clinical validation and provide evidence of studies. ClearRead CT highlights a selection of research, peer reviews, reference accounts, and independent studies on its website. EchoNext has published studies in Nature and Nature Medicine and has publicly released model weights and datasets for further development and transparency. Without specific details on customer support channels, training programs, or comprehensive documentation availability for either tool, it is not possible to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	ClearRead CT	EchoNext
Company	RIVERAIN TECHNOLOGIES	Pathway Labs
Description	ClearRead CT is an FDA-cleared AI suite by Riverain Technologies for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. It improves diagnostic accuracy, reduces reading times, and streamlines radiology workflows through advanced AI and vessel suppression technology.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Categories	Cardiology AI, Oncology AI, Radiology & Imaging AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Specialties	Cardiology, Pulmonology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine
Key Features	Pulmonary Nodule Detection (solid, part-solid, ground glass), Patented Vessel Suppression (Clear Visual Intelligence), Nodule Characterization and Measurement (volume, diameter, location, type, depth), Automated Nodule Tracking and Comparison to Prior Exams, Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs), Reduced Reading Time (up to 36%), Improved Detection Accuracy (29% reduction in missed actionable nodules), Seamless PACS Integration / Vendor-neutral processing	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring ClearRead CT and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

ClearRead CT offers seamless PACS integration, allowing radiologists to view the AI-processed series alongside original CT scans without needing a separate application or login. It also supports configurable output formats for integration with other workflow tools and offers optional worklist integration and pre-populated reports. EchoNext integrates with the OpenEvidence clinical decision support platform, which is used by many physicians, allowing its screening output to be directly accessible within existing clinical workflows.

What is the accuracy and sensitivity of each tool in detecting relevant clinical conditions?

ClearRead CT has been shown to improve detection accuracy by 29% for missed actionable nodules and reduces reading time by up to 36%. Its per-nodule sensitivities were reported as 84% for solid nodules, 85% for part-solid nodules, and 67% for ground-glass nodules. EchoNext demonstrated high accuracy in identifying structural heart problems, including heart failure, valve disease, and pulmonary hypertension, outperforming cardiologists in a head-to-head comparison with 77% accuracy versus 64% for cardiologists.

What is the typical learning curve for physicians adopting these AI tools?

ClearRead CT is designed for intuitive use and seamless integration into existing PACS workflows, suggesting a potentially low learning curve for radiologists as it presents information as an additional series without requiring new applications or logins. EchoNext is integrated into the OpenEvidence platform, which many physicians already use, implying that the learning curve might be minimal as it leverages a familiar interface for delivering its insights.

What kind of customer support and resources are available for these tools?

Riverain Technologies provides customer care via email and phone, with hours from M-F 8:30 AM to 8:30 PM EST, and offers resources such as FAQs, series recommendations, system requirements, workflow guides, and manuals. For EchoNext, support would likely be facilitated through Pathway Labs and its partnership with OpenEvidence, though specific details on support quality and resources are not explicitly stated.

Are there audit-trail features available to track how the AI influenced diagnostic decisions?

ClearRead CT generates reports that summarize findings and integrates these into the radiology report, and it also automatically tracks and compares nodules to prior exams, which could contribute to an audit trail. The available information for EchoNext does not explicitly detail audit-trail features, but its integration into a clinical decision support platform suggests potential for tracking AI-driven insights within that system.

What are the considerations for rolling out these tools across multiple clinical sites or a large healthcare system?

ClearRead CT offers enterprise-wide capability, processing scans from all CT manufacturers and acquisition protocols, making it suitable for multi-site deployment. It has been deployed across networks like Duke University Medical Center and the VA healthcare system, indicating its scalability. EchoNext is designed for broad access, from major hospitals to community practices, and its partnership with OpenEvidence aims to facilitate national-scale deployment across various health systems.

In what clinical contexts would a physician choose one tool over the other?

A physician would choose ClearRead CT primarily for cardiothoracic imaging, specifically for enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans, especially when aiming to reduce reading times and improve detection accuracy of various nodule types. EchoNext would be chosen by physicians, including cardiologists, family medicine, hospital medicine, and internal medicine specialists, for early, non-invasive screening of hidden structural heart disease, such as heart failure, valve disease, and pulmonary hypertension, using standard ECGs to identify patients who may need further echocardiogram evaluation.